INTELLIGENT BIO SOLUTIONS INC.
For the period ended Jun 30, 2025. Filed Aug 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Aug 15, 2025
INBS$2.25-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended June 30, | ||||
|---|---|---|---|---|
| 2025 · 2024 | ||||
| Cash Flows from Operating Activities | ||||
| Net loss | $(10,604,886) | $(10,190,932) | ||
| Adjustments to reconcile net loss to cash used in operating activities: | ||||
| Depreciation and amortization | 970,117 | 974,355 | ||
| Amortization of right-of-use assets | 243,632 | 238,730 | ||
| Impairment of long-lived assets | 220,062 | - | ||
| Non-cash loss on foreign currency translation, net | - | 1,178 | ||
| Provision for credit losses | 546 | 6,772 | ||
| Provision for inventory obsolescence | - | 69,676 | ||
| Stock-based compensation | 238,045 | 230,496 | ||
| Non-cash refund of R&D expenditure claims | (137,696) | - | ||
| Fair value gain on revaluation of holdback Series C Preferred Stock | - | (175,738) | ||
| Non-cash other operating activities | 113,645 | (24,177) | ||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | (164,910) | (135,843) | ||
| Inventories | 142,322 | 202,370 | ||
| Grant receivable / deferred grant income | (2,486,668) | 148,611 | ||
| Research and development tax incentive receivable | (209,076) | (26,574) | ||
| Other current assets | (329,404) | 55,219 | ||
| Accounts payable and accrued expenses | 2,577,151 | (632,950) | ||
| Long-term employee benefit liabilities | 21,306 | (364,149) | ||
| Operating lease liabilities | (271,499) | 51,387 | ||
| Net cash used in operating activities | (9,677,313) | (9,571,569) | ||
| Cash Flows from Investing activities | ||||
| Purchase of property and equipment | (231,838) | (221,426) | ||
| Net cash used in investing activities | (231,838) | (221,426) | ||
| Cash flows from Financing Activities | ||||
| Proceeds from issuance of common stock and warrants, net of issuance costs | 4,589,866 | 3,786,164 | ||
| Proceeds from exercise of warrants, net of issuance costs | 7,939 | 1,656,811 | ||
| Proceeds from private placement, net of issuance costs | - | 9,117,581 | ||
| Net cash provided by financing activities | 4,597,805 | 14,560,556 | ||
| Effect of foreign exchange rates on cash and cash equivalents | 27,157 | (707) | ||
| Net decrease (increase) in cash and cash equivalents | (5,284,189) | 4,766,854 | ||
| Cash and cash equivalents, beginning of period | 6,304,098 | 1,537,244 | ||
| Cash and cash equivalents, end of the period | $1,019,909 | $6,304,098 | ||
| Non-cash investing and financing activities | ||||
| Equity issuance costs in accounts payable and accrued expenses | $14,999 | $ | - | |
| Conversion of preferred shares into common shares | $ | - | $57,287 | |
| Conversion of holdback Series C Preferred Stock into common stock | $ | - | $32,762 | |
| Issuance of common stock upon cashless exercise of Series F warrants | $55 | $6,551 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.